Cardiovascular Disease: Saving the Hearts of Women Through Prevention is organized by Healio.
Release Date: October 31, 2023
Expiration Date: October 30, 2024
Activity Description
Cardiovascular disease (CVD) is the leading cause of death globally, and women are disproportionately affected, showing higher morbidity and mortality rates than men. This trend has continued despite awareness campaigns and recent advances in gender-based guidelines as well as effective, available therapies.
In the United States, heart disease is the leading cause of death, and women have significantly higher 30-day mortality rates after a new CVD event compared with men. In addition to traditional cardiovascular (CV) risk factors, women often possess several nontraditional risk factors, related to pregnancy, hormonal influences, or comorbid disorders. Furthermore, women are less likely to receive guideline-recommended diagnostic testing and therapies. In this interactive, case-based program, expert faculty address CVD risk factors, diagnostic tools, and guidelines related to screening women for CV risk. They also examine challenges in the measurement of lipoprotein a [Lp(a)], as well as clinical evidence for current and emerging therapies to manage women with elevated Lp(a). Evidence-based strategies on using non-statin therapies to reduce low-density lipoprotein cholesterol (LDL-C) in women will also be reviewed. This program includes the unique, audience-engaging, educational gaming platform, Wheel of Knowledge Challenge!
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
• Examine gender-specific factors that have an impact on CV risk in women.
• Evaluate guideline recommendations and appropriate modalities to screen women for CV risk.
• Describe the challenges in the measurement of Lp(a) and evidence-based approaches to identify women with elevated Lp(a) who may be at risk for CV events.
• Outline the clinical evidence for current and emerging therapies to manage women with elevated Lp(a).
• Review evidence-based strategies to emphasize the significance of achieving recommended LDL-C targets and implications for CV risk.
• Summarize recent data regarding the impact of non-statin therapies on the reduction of LDL-C in women with atherosclerotic cardiovascular disease (ASCVD).